SEC 13F Intelligence

Managers / Q4 2018 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$106M
Q4 2018
Positions
52
Filings on Record
39
2019–present window
Filed
Feb 6, 2019
original filing

Summary

Birchview Capital, LP reported $106M in U.S.-listed holdings across 52 positions for Q4 2018.

The portfolio is heavily concentrated: CELG alone accounts for 42.4% of reported value.

Portfolio Metrics

Top-10 Concentration
+83.0%
share of reported value
Largest Position
+42.4%
Celgene Corp Celg

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 65.5%Other: 32.4%MLP: 2.0%
  • Common Stock · 65.5% · $69M
  • Other · 32.4% · $34M
  • MLP · 2.0% · $2M

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
CELGCELGENE CORP (CELG)NEW+699.0K699.0K+$45M$45M
ACCELERATE DIAGNOSTICS INCNEW+2.18M2.18M+$25M$25M
NBIXNEUROCRINE BIOSCIENCES INCNEW+55.0K55.0K+$4M$4M
CLEMENTIA PHARMACEUTICALS INCNEW+222.0K222.0K+$3M$3M
ARRYEURARRAY BIOPHARMA INCNEW+168.0K168.0K+$2M$2M
QDEL*QUIDEL CORPNEW+47.1K47.1K+$2M$2M
EQMUSDEQM MIDSTRM PRTNERS LP LTDNEW+50.0K50.0K+$2M$2M
VNDAVANDA PHARMACEUTICALS INCNEW+80.0K80.0K+$2M$2M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2018

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CELGCELGENE CORP (CELG)history →COM42.38%$45M699.0K
2ACCELERATE DIAGNOSTICS INCCOM23.76%$25M2.18M
3NBIXNEUROCRINE BIOSCIENCES INChistory →COM3.72%$4M55.0K
4CLEMENTIA PHARMACEUTICALS INCCOM2.47%$3M222.0K
5ARRYEURARRAY BIOPHARMA INChistory →COM2.26%$2M168.0K
6QDEL*QUIDEL CORPhistory →COM2.17%$2M47.1K
7EQMUSDEQM MIDSTRM PRTNERS LP LTDhistory →UNIT LTD PARTN2.05%$2M50.0K
8VNDAVANDA PHARMACEUTICALS INChistory →COM1.98%$2M80.0K
9ATRAGBXATARA BIOTHERAPEUTICS INChistory →COM1.12%$1M34.0K
10SOLENO THERAPEUTICS INCCOM1.06%$1M656.6K
11OXFORD IMMUNOTEC GLOBAL PLCCOM0.97%$1M80.3K
12IMPRIMIS PHARMACEUTICALS INCCOM0.97%$1M180.0K
13BDQMALBIREO PHARMA INCCOM0.88%$932,00038.0K
14MASI*MASIMO CORPCOM0.81%$859,0008.0K
15ARNAEURARENA PHARMACEUTICALS INCCOM0.81%$857,00022.0K
16WRIGHT MEDICAL GROUP NVCOM0.77%$817,00030.0K
17XLRNACCELERON PHARMA INCCOM0.77%$813,00018.7K
18BIIBBIOGEN INCCOM0.71%$752,0002.5K
19HTDCORCEPT THERAPEUTICS INCCOM0.63%$668,00050.0K
20KPTIEURKARYOPHARM THERAPEUTICS INCCOM0.62%$656,00070.0K
21VERMILLION INCCOM0.60%$634,0002.11M
22VCYTVERACYTE INCCOM0.58%$613,00048.8K
23INFLARX NVCOM0.55%$582,00016.0K
24AMARIN CORP PLCSPONS ADR NEW0.51%$544,00040.0K
25SIENUSDSIENTRA INCCOM0.48%$508,00040.0K
26PXDEURPIONEER NATURAL RESOURCES COCOM0.47%$500,0003.8K
27DRNAUSDDICERNA PHARMACEUTICALS INCCOM0.46%$481,00045.0K
28XNCRXENCOR INCCOM0.42%$445,00012.3K
29ICPTUSDINTERCEPT PHARMACEUTICALS INCCOM0.41%$433,0004.3K
30ARVNARVINAS INCCOM0.37%$386,00030.0K
31CFRXEURCONTRAFECT CORPCOM0.35%$368,000240.2K
32AM6AMICUS THERAPEUTICS INCCOM0.34%$364,00038.0K
33CLRUSDCONTINENTAL RESOURCES INCCOM0.30%$322,0008.0K
34ENCANA CORPCOM0.30%$320,00055.3K
35NKTREURNEKTAR THERAPEUTICSCOM0.30%$312,0009.5K
36VYGRVOYAGER THERAPEUTICS INCCOM0.29%$310,00033.0K
37DOVADOVA PHARMACEUTICALS INCCOM0.29%$303,00040.0K
38MYGNMYRIAD GENETICS INCCOM0.28%$291,00010.0K
39GTHXEURG1 THERAPEUTICS INCCOM0.27%$287,00015.0K
40ODONATE THERAPEUTICS INCCOM0.27%$282,00020.0K
41EQTEQT CORPORATIONCOM0.20%$213,00011.3K
42AMAGAMAG PHARMACEUTICALS INCCOM0.14%$152,00010.0K
43LTHM1EURLIVENT CORPCOM0.13%$138,00010.0K
44LXRXLEXICON PHARMACEUTICALS INCCOM NEW0.13%$133,00020.0K
45ONCOMED PHARMACEUTICALS INCCOM0.12%$129,000172.6K
46STTOSITO MOBILE LTDCOM0.12%$126,000140.0K
47IMGNEURIMMUNOGEN INCCOM0.10%$106,00022.0K
48YIELD10 BIOSCIENCE INCCOM0.09%$97,000122.1K
49AEVI GENOMIC MEDICINE INCCOM0.09%$90,000128.0K
50CYTKCYTOKINETICS INCCOM0.06%$63,00010.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.